Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Plasma exosome miRNA marker suitable for pancreatic ductal adenocarcinoma diagnosis and prognosis and application

A technology for pancreatic ductal adenocarcinoma and prognosis judgment, which is applied in the field of medical biological detection, can solve the problem of lack of PDAC diagnosis and prognosis kits, etc., achieves the effect of convenient and easy diagnosis, and improves the clinical treatment effect.

Active Publication Date: 2019-05-21
SHANGHAI CHANGHAI HOSPITAL
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there is no report on the diagnostic and prognostic kits for PDAC. If relevant kits can be developed and used clinically, it will definitely play an important role in guiding the clinical diagnosis and treatment of PDAC.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Plasma exosome miRNA marker suitable for pancreatic ductal adenocarcinoma diagnosis and prognosis and application
  • Plasma exosome miRNA marker suitable for pancreatic ductal adenocarcinoma diagnosis and prognosis and application
  • Plasma exosome miRNA marker suitable for pancreatic ductal adenocarcinoma diagnosis and prognosis and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] 1. Research object: To study the difference of plasma exosomal miRNA expression profile between PDAC and chronic pancreatitis

[0037] The present invention was included in training group and verification group 141 examples ( figure 1 ), after excluding non-PDAC and severe hemolysis (grade 5 or above), a total of 90 patients were included. Blood samples from 90 patients with PDAC or CP were collected from the clinical blood sample bank of Changhai Hospital.

[0038] 2. Research methods

[0039] 1. Blood samples were collected before the patients were admitted to the hospital for medication and surgery; 5ml of peripheral venous blood was drawn from each patient and stored in a vacuum anticoagulant tube (REF367863; Becton Dickinson, Franklin Lakes, NJ, USA). Blood samples were stored at 4°C within 1 hour.

[0040] 2. Plasma purification: samples were centrifuged at 4°C and 1600×g for 10 minutes, and the hemolysis was recorded. In this study, samples with a hemolysis le...

Embodiment 2

[0048] Example 2: Find out miRNA markers that can diagnose PDAC metastasis and correlate with prognosis

[0049] 1. Research object

[0050] From June 2017 to June 2018, a total of 141 cases in the training group and verification group were included in this study ( figure 1 ), after excluding non-PDAC and severe hemolysis (grade 5 or above), there were 90 remaining patients, including 65 PDAC patients, 34 non-metastatic cases, and 21 metastatic cases. The blood samples of the patients were obtained from the clinical blood sample bank of Changhai Hospital.

[0051] 2. Research Methods

[0052] With embodiment 1.

[0053] Analyze the similarities and differences in plasma exosomal miRNA expression between transferred and non-transferred PDAC, and perform pathway enrichment analysis on the identified miRNAs; analyze in TCGA data, and analyze the differences in prognosis between individuals with different expressions of tissues and miRNAs.

[0054] 3. Research results

[0055...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medical biological detection, and particularly provides a plasma exosome miRNA marker suitable for pancreatic ductal adenocarcinoma diagnosis and prognosis and application of the marker in preparing a diagnosis reagent or kit for pancreatic ductal adenocarcinoma. The bio-marker which has high diagnosis and differential diagnosis value for the pancreatic ductal adenocarcinoma is found for the first time, and the bio-marker comprises plasma exosome miRNA-95-3p, miRNA-26b-5p and miRNA-335-5p. By means of development and application of the miRNA marker and the diagnosis kit, more precise diagnosis is made for the pancreatic ductal adenocarcinoma, especially, the marker and the diagnosis kit assist clinicians in differential diagnosis of the pancreatic ductal adenocarcinoma and chronic pancreatitis, meanwhile, prognosis of patients is evaluated, and a foundation is laid for the clinicians to accurately grasp the illness states of the patientsand for improving the clinical treatment effect.

Description

technical field [0001] The invention relates to the technical field of medical biological detection, specifically, a plasma exosome miRNAs marker suitable for the diagnosis and prognosis of pancreatic ductal adenocarcinoma and its detection application. Background technique [0002] Pancreatic ductal adenocarcinoma (Pancreatic Ductal Adenocarcinoma, PDAC) is the fourth leading cause of cancer-related death in the United States and is expected to rise to the second place by 2020 (Siegel RL, Miller KD, Jemal A. Cancerstatistics, 2018[J].CA Cancer J Clin, 2018, 68(1):7-30.). Delayed diagnosis and lost opportunity for surgery is an important reason affecting the survival rate of PDAC. The median survival period of patients with PDAC metastasis is 6 to 12 months, and the overall 5-year survival rate of PDAC patients is 8% (Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018 , 68(1):7-30). [0003] Clinically, the differential diagnosis of PDAC and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886
Inventor 金钢郭世伟王欢
Owner SHANGHAI CHANGHAI HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com